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A b s t r a c t
Background: The Systemic COronary Risk Estimation (SCORE) system is recommended for the assessment of cardiovascular 
disease (CVD) death risk in individuals free of CVD.
Aim: We sought to determine the association between carotid-femoral pulse wave velocity (CFPWV) and SCORE.
Methods: The study involved 1008 Krakow residents, and a random subsample of 3424 men and 3205 women who participated 
in Wave 2 of the Polish part of the Health, Alcohol, and Psychosocial factors in Eastern Europe (HAPIEE) study. At baseline we 
performed a medical interview, physical examination, evaluation of present comorbidities, medications using standardised 
methods. A follow-up of 4.9 years included measurement of CFPWV using an automatic, computerised Complior® system.
Results: Final analysis included 720 patients (378 women), aged 58.5 ± 6.5 years at baseline. In 488 individuals without his-
tory of CVD and/or diabetes, SCORE was calculated. Median CFPWV was higher (p = 0.002) in men (12.5 m/s; interquartile 
range [IQR] 10.3–15.7) than in women (11.7 m/s; IQR 10.1–13.7). High CFPWV (> 10 m/s) was observed in 270 men (78.9%) 
and in 285 women (75.4%). We observed a strong association between high CVD risk (SCORE ≥ 5%) and high CFPWV (odds 
ratio 2.29; 95% confidence interval 1.17–4.46). The CFPWV cut-off value to differentiate between patients with low and high 
CVD risk was 11.7 m/s (with 58.6% sensitivity and 71.3% specificity, AUC = 0.68).
Conclusions: Our study is the first to describe the distribution of CFPWV in the adult Polish population. SCORE ≥ 5% pre-
dicted high CFPWV in 4.9 years of follow-up, which was independent of other risk factors. CFPWV > 11.7 m/s was most 
valid in relation to high CVD risk.
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INTRODUCTION
Arterial stiffness is a biomechanical property of the arterial wall 
expressed as a change of pressure-volume relationship [1–3]. 
Carotid-femoral pulse wave velocity (CFPWV) is the most 
common method widely used for aortic stiffness measure-
ment [3]. It has been shown that increased CFPWV correlates 
with an increased risk of cardiovascular death in patients 
with hypertension [4, 5] and type 2 diabetes (T2D) [6, 7]. 
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Furthermore, CFPWV was an independent predictor of coro-
nary artery disease (CAD) [8] and was recognised as a new 
risk factor of morbidity and mortality in cardiovascular (CV) 
disease (CVD) [9]. CFPWV is a useful non-invasive method for 
measuring the stiffness of the aorta because of its simplicity, 
repeatability, and accuracy. According to the recent European 
Society of Cardiology (ESC)/European Society of Hypertension 
(ESH) guidelines for hypertension, pulse wave velocity (PWV) 
may be considered in the assessment of arterial stiffness as 
an integral part of the overall assessment of subjects with 
hypertension [10].
The association between CFPWV and a single risk factor 
such as hypertension is well-known; however, SCORE and 
CFPWV analysis, although not well documented, indirectly 
estimates how the PWV affects the 10-year risk of death due 
to CVDs. 
Moreover, CFPWV was proven to predict CVD in a variety 
of populations independently of traditional CV risk factors 
[4, 11]. Therefore, the 2013 ESH/ESC guidelines for the man-
agement of hypertension recommend measuring CFPWV as 
a marker of target organ damage in order to improve CV risk 
prediction [12–14]. The objective of this study was to evalu-
ate the association between CVD risk factors and CVD risk 
assessed by Systematic COronary Risk Evaluation (SCORE) and 
CFPWV measured four years later. Additionally, our goal was 
to describe the distribution of CFPWV in adult urban Polish 
population and to estimate the cut-off point for CFPWV which 
is related to SCORE ≥ 5%.
METHODS
Patients
The study involved 1008 Krakow residents (478 men and 
530 women), aged 58.5 ± 6.5 years, and a random (chosen 
based on a random number generator programme) subsample 
of 3424 men and 3205 women who participated in Wave 1 
and Wave 2 (4.9 years apart) of the Polish part of the Health, 
Alcohol, and Psychosocial factors in Eastern Europe (HAPIEE) 
study. In Wave 1, to assess risk factors, the study participants 
were visited at home to complete a structured questionnaire 
and were then invited to a clinic for a thorough medical in-
terview to evaluate comorbidities and medications, and for 
a physical examination. Detailed information on the HAPIEE 
study, which involved a representative sample of permanent 
residents of Krakow, was published earlier [15].
For the present analysis, current smoking was defined as 
smoking at least one cigarette daily. Prior to the blood pres-
sure (BP) measurement, participants were asked to sit quietly 
for 5–10 min. BP was measured three times, with a 2-min 
interval between measurements, which was done using an 
Omron M5-I device (Omron Healthcare, Kyoto, Japan). Arte-
rial hypertension was defined as a systolic BP ≥ 140 mmHg, 
or diastolic BP ≥ 90 mmHg, or taking antihypertensive drugs 
within the last 14 days prior to the examination. History of 
CAD was established based on a medical interview includ-
ing documented history of myocardial infarction (MI) or 
prior cardiac procedures of CAD. T2D diagnosis was based 
on medical history of T2D treatment or American Diabetes 
Association criteria. Obesity was diagnosed when body mass 
index (BMI) ≥ 30 kg/m2 or waist circumference ≥ 94 cm in men 
or 80 cm in women. Family history of CAD, stroke, or T2D 
was considered positive when at least one of the first-degree 
relatives had a history of at least one of the diseases.
The Jagiellonian University Ethical Committee approved 
the study, and all the participants provided their written, 
informed consent (No. KE/99/03/B/284, amendment from 
March 13, 2008).
Sample collection and routine laboratory tests 
Fasting blood samples (25 mL) were obtained from an an-
tecubital vein and were immediately drawn into the tubes 
containing 3.2% trisodium citrate. Samples were processed 
30 to 60 min after blood collection. Serum total cholesterol 
(TC), low-density lipoprotein cholesterol (LDL-C), high-density 
lipoprotein cholesterol (HDL-C), triglyceride (TG), and glucose 
were determined using a Cobas 6000™ biochemical analyser 
(Roche Diagnostics GmbH, Mannheim, Germany). Dyslipi-
daemias including hypercholesterolaemia and hypertriglyc-
eridaemia were diagnosed in accordance with the European 
Guidelines on CVD prevention and dyslipidaemias [16].
Measurement of CFPWV
Carotid-femoral pulse wave velocity was measured in 
Wave 2 of the HAPIEE study. To assess CFPWV we used the 
non-invasive, automatic, computerised Complior® system in 
accordance with the system protocol. All measurements were 
performed after a 10 min rest in a supine position (~30°). 
Mechanical transducers sensitive to deformation of the vessel 
wall were applied over the common carotid artery and right 
femoral artery. Then, the distance between the suprasternal 
notch and the top of the femoral transducer were calculated 
on the surface of the body with a measuring tape. The CFPWV 
was calculated by dividing distance (d) of the wave from the 
carotid to femoral artery over time (t) as shown below [17]: 
CFPWV = d/t.
Carotid-femoral pulse wave velocity values > 10 m/s 
were defined as “high” according to the current guidelines 
of the ESC and the ESH [10, 18, 19].
SCORE assessment
The SCORE system is a calculation of the 10-year risk of a fa-
tal CVD in European countries by sex, age, systolic BP, TC, 
and smoking status [16, 20]. For eligible participant (without 
a history of CAD and/or T2D), CVD risk was assessed using 
the SCORE system calibrated for Poland available on the ESC 
website (www.heartscore.org; access from January 2007 to 
December 2009) [21].
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Statistical analysis
The Shapiro-Wilk test was used to assess the normality of 
distribution. Distribution of the continuous variables was de-
scribed by mean and standard deviation (SD) or median and 
interquartile range (IQR). The Student t test or Mann-Whitney 
U test was applied to test the between-sex differences. For 
categorical variables, an absolute number and percentage 
was presented and the between-sex differences were tested 
using the c2 test. Spearman rank correlation coefficients were 
calculated to test the association between the continuous 
variables. Stepwise logistic regression analysis was performed 
to determine the independent predictors of increased 
CFPWV in the study groups. Despite differences in distribution 
of characteristics between men and women, the direction and 
pattern of the association between these variables and CFPWV 
were homogeneous. Therefore, data were pooled for multivariate 
analysis including sex as an independent variable. The association 
between the variables was presented as odds ratio (OR) with 
corresponding 95% confidence interval (CI). The calibration 
and discrimination of the developed logistic regression model 
were assessed using the Hosmer-Lemeshow statistic and the area 
under the receiver operating characteristic curve (AUC), respec-
tively. Two-sided p-values < 0.05 were considered statistically 
significant. All calculations were done using STATISTICA version 
10 PL software package (StatSoft, Inc., Tulsa, Oklahoma, USA).
RESULTS
Final analysis included 720 participants (378 women and 
342 men). At baseline (Wave 1), mean age was 58.1 and 
58.8 years, respectively. At Wave 2, participants were older 
by an average of 4.9 years (4.9 in men and 4.8 in women; 
Table 1). A total of 179 (24.9%) participants had previously 
diagnosed CAD and 97 had history of T2D, and SCORE was 
not calculated for these individuals because by definition they 
were considered high-risk subjects. Therefore, final analysis 
for SCORE included 229 men and 259 women.
The CFPWV ranged from 2.3 to 37.5 m/s in men and 
from 2.4 to 31.8 m/s in women. The distribution of CFPWV 
was skewed in both sexes, and the median was higher in 
men (12.5 m/s; IQR 10.3–15.7) than in women (11.7 m/s; 
IQR 10.1–13.7); p = 0.002 (Fig. 1). For the entire sample 
CFPWV ranged from 2.3 to 37.5 m/s and the median CFPWV 
was 12.0 m/s (IQR 10.2–14.7). High CFPWV (> 10 m/s), 
which is considered abnormal [14, 19], was observed in 
270 (78.9%) men and in 285 (75.4%) women. In the entire 
sample 555 (77.1%) individuals had high CFPWV.
The distribution of SCORE was skewed particularly 
in women (Fig. 2). Median SCORE was higher in men 
(9.0%; IQR 5.0–14.0) than in women (3.0%; IQR 1.0–6.0); 
p < 0.001. High risk (SCORE ≥ 5%) was found in 28.6% of 
women and in 77.7% of men (p < 0.001).
Descriptive statistics for the remaining traits that were 
analysed are presented according to sex in Table 1. Smok-
ing and T2D were more prevalent in men, and BP was not 
significantly higher in men than in women. TC and HDL-C 
were higher in women, and TGs were higher in men. There 
was no between-sex difference in LDL-C, and there was no 
difference in the combined prevalence of dyslipidaemias. The 
prevalence of obesity was similar in men and women, but 
the median waist circumference was lower in women, which 
reflects the between-sex differences in body constitution. 
After adjustment for baseline age, the risk of high CFPWV 
(> 10 m/s) increased with the increase of systolic BP in both 
sexes and with diastolic BP and the presence of hypertension 
in women. In women the risk of high CFPWV increased with 
the increase of BMI and waist circumference. We found a posi-
tive association between CFPWV and both blood glucose and 
TC, but only in male population. In women with no history of 
CVD or T2D (n = 488), there was a positive relation between 
the high CFPWV and SCORE (OR 1.42; 95% CI 1.11–1.81 per 
1% increase). The relation between the high CFPWV and 
SCORE was not significant in men (Table 2). Triglycerides and 
smoking as well as other characteristics listed in Table 1 were 
not associated with high CFPWV.
In individuals without CVD or T2D, after adjustment 
for age, sex, BMI, blood TG, and glucose, we did not found 
a continuous relation between SCORE and CFPWV. It was at-
tenuated and remained not significant mainly after inclusion of 
the age into the model. However, there was a strong relation 
between high CVD risk (SCORE ≥ 5%) and high CFPWV (OR 
2.29; 95% CI 1.17–4.46). Further analysis after subdivision 
of the group with high CVD risk (SCORE > 5%) changed the 
average estimates (OR 2.29; 95% CI 1.15–4.55 for SCORE 
5%–9%; and OR 2.27; 95% CI 0.92–5.62 for SCORE ≥ 10%).
The calculated CFPWV cut-off value to differentiate 
between participants with low and high CVD risk (SCORE 
of < 5% vs. SCORE ≥ 5%) was 11.7 m/s (with 58.6% sensitivity 
and 71.3% specificity, AUC = 0.68).
DISCUSSION
Knowledge about the association between CFPWV and 
the result of commonly used CVD risk assessment systems 
such as the SCORE system is still limited [22–24]. Because 
most European countries use different SCORE charts, it is 
particularly important to assess its results with other measure-
ments. This could improve the quality of CVD predictions in 
this particular population, including subpopulations, that is, 
men and women. Therefore, to our knowledge, we are first 
to demonstrate the association of CFPWV and the SCORE 
system in any Polish population.
We demonstrated that high CVD risk assessed by the 
SCORE system predicted high CFPWV at almost five years 
of follow-up. A continuous relation between SCORE and 
high CFPWV was attenuated after adjustment for covariates, 
particularly for age, which suggests a confounding effect that 
was not strong enough to wave the relation for the range 
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Table 1. Demographic and clinical data of the study participants (n = 720)
Variable Women (n = 378) Men (n = 342) p
Baseline age (Wave 1) [years] 58.1 ± 6.5 58.8 ± 6.4 0.156
Age at Wave 2 [years] 63.0 ± 6.5 63.7 ± 6.5 0.144
Average follow-up time [years] 4.8 ± 0.3 4.9 ± 0.3 0.291
BMI [kg/m2] 27.1 (23.8–29.8) 27.1 (25.0–29.7) 0.437
Waist circumference [cm] 91.0 (82.0–98.0) 99.0 (93.0–106.0) < 0.001
Obesity 91 (24.1) 74 (21.6) 0.437
CAD 103 (27.2) 76 (22.2) 0.12
Type 2 diabetes: 37 (9.8) 60 (17.5) 0.002
Treated with diet only 9 (2.4) 20 (5.9) 0.030
Treated with diet and insulin 2 (0.5) 5 (1.5)
Treated with diet and oral medications 21 (5.6) 28 (8.2)
Untreated 5 (1.3) 7 (2.1)
Hypertension: 207 (54.8) 199 (58.2) 0.355
Treated with antihypertensives 152 (40.2) 140 (40.9) 0.513
Never treated 55 (14.6) 59 (17.3)
Dyslipidaemia 202 (53.4) 163 (47.7) 0.121
Consistent daily smokers 69 (18.3) 94 (27.5) < 0.001
Occasional smokers 10 (2.7) 8 (2.3)
Former smokers 72 (19.1) 113 (33.0)
Never smokers 227 (60.1) 127 (37.1)
Family history of CAD 135 (35.7) 107 (31.3) 0.209
Family history of stroke 29 (7.7) 15 (4.4) 0.066
Family history of type 2 diabetes 50 (13.2) 38 (11.1) 0.387
SCORE scale [%] (n = 488) 3.0 (1.0–6.0) 9.0 (5.0–14.0) < 0.001
≤ 4% 185 (71.4) 51 (22.3) < 0.001
5–9% 57 (22.0) 85 (37.1)
≥ 10% 17 (6.6) 93 (40.6)
Systolic BP [mmHg] 129.8 (117.0–145.5) 139.0 (128.0–151.0) < 0.001
Diastolic BP [mmHg] 82.5 (76.0–91.0) 88.0 (80.5–94.0) < 0.001
Mean arterial pressure [mmHg] 98.4 (99.9–108.4) 104.7 (97.2–112.8) < 0.001
Glucose [mmol/L] 5.0 (4.6–5.5) 5.2 (4.8–5.8) < 0.001
Heart rate [bpm] 74.0 (67.5–82.5) 73.5 (66.0–82.0) 0.451
TC [mmol/L] 5.80 (5.12–6.54) 5.59 (4.99–6.28) 0.008
HDL-C [mmol/L] 1.52 (1.26–1.82) 1.29 (1.08–1.48) < 0.001
LDL-C [mmol/L] 3.57 (2.98–4.20) 3.53 (2.99–4.10) 0.810
TG [mmol/L] 1.30 (1.01–1.84) 1.49 (1.13–2.07) < 0.001
CFPWV [m/s] (measured at 4.9 years of follow-up) 11.7 (10.1–13.7) 12.5 (10.3–15.7) 0.002
Data presented as number (percentage), mean ± standard deviation or median (interquartile range). BMI — body mass index; BP — blood pressure; 
CAD — coronary artery disease; CFPWV — carotid-femoral pulse wave velocity; HDL-C — high-density lipoprotein cholesterol; LDL-C — low-density 
lipoprotein cholesterol; SCORE — Systemic COronary Risk Estimation; TC — total cholesterol;  TG — triglycerides
of SCORE over 5%. The calculated CFPWV cut-off point of 
11.7 m/s allowed us to classify participants of the study to the 
high CVD risk group with optimal sensitivity and specificity. 
The SCORE system is a well-recognised tool used to evalu-
ate 10-year CVD risk. On the other hand, the SCORE system 
was calibrated for specific countries, which allowed adjust-
ment for CVD mortality and exposure to risk factors. Poland is 
a country with high exposure to CVD risk factors [25–28]. The 
most frequent CVD risk factors in Poland are hypercholester-
olaemia, hypertension, and cigarette smoking [29]. Our results 
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Figure 2. Distribution of Systemic COronary Risk Evaluation (SCORE) by sex in the study population; A. Men; B. Women.  
Data shown as percentage of the study population and percentage of SCORE system
Figure 1. Distribution of carotid-femoral pulse wave velocity (CFPWV) by sex in the study population. A. Men; B. Women. Data 
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are in accordance with another study which demonstrated 
that arterial stiffness (assessed by CFPWV among other param-
eters) was also positively associated with SCORE, but in that 
study the authors did not attempt to assess a cut-off point for 
CFPWV, which allowed to classify the participants into the 
high and low CVD risk groups [22].
In the 2013 ESC guidelines for the management of arterial 
hypertension, a measurement of CFPWV was recommended 
in all individuals with arterial hypertension [14, 19]. However, 
in the 2018 ESH/ESC guidelines there was no such recom-
mendation. Nevertheless, PWV is considered as one of the 
key factors influencing CV risk in patients with asymptomatic 
hypertension-mediated organ damage [10]. Moreover, CFPWV 
over 10 m/s was for many years considered a risk factor for 
CVD [14, 19]. Greve et al. [30] analysed the data from over 
2500 patients and demonstrated an increase in the CFPWV 
associated with atherosclerotic plaques and increased rate of 
albuminuria to creatinine ratio depending on the high and very 
high risk assessed by the SCORE system and Framingham risk 
scale. The authors emphasised that PWV better predicted CVD 
complications in high-risk subjects [30]. It was reported that 
PWV is associated with the severity of CAD: 11.13 ± 0.91 m/s, 
15.22 ± 1.11 m/s, and 19.30 ± 2.05 m/s for one-, two-, and 
three-vessel CAD, respectively [31]. Similarly, Kopeć et al. [32] 
observed that increased aortic wall stiffness (aortic PWV) was 
associated with the severity of CAD. Invasive measurements 
of aortic PWV were linked with worse endothelial function in 
patients with angiographically confirmed CAD, independent 
of sex [32]. Higher CFPWV was also observed in individuals 
with microvascular angina compared to a healthy control group 
(9.3 m/s vs. 8.2 m/s, respectively) [33]. Recent studies show that 
the assessment of PWV as an indicator of arterial stiffness is still 
a widely used parameter [34, 35].
We have several limitations to acknowledge. The most 
important is that we were not able to adjust for the baseline 
CFPWV, which did not allow us to address the problem of 
overtime change and limited our ability to address the prob-
lem of causality. Also, there was no information on changes 
in the exposure to risk factors after the baseline examination, 
so their directions and magnitudes could not be evaluated. 
Second, age as a CVD risk factor interferes with arterial stiff-
ness and, by definition, is associated with the results of the 
SCORE system. Third, our study population was not repre-
sentative of the entire Polish population and involved a local 
population of residents of one city (second largest city in 
Poland). Further, earlier observations of the HAPIEE cohort 
showed that study participants were healthier compared to 
non-participants. Still, nearly 6% of the total sample examined 
at baseline did not survive to participate in PWV measurement 
at five years of follow-up [36]. The latter could lead to elimi-
nation of the high-risk group, and it is possible that it could 
attenuate slightly the relation between SCORE and CFPWV. 
Fourth, as mentioned above, the SCORE system appeared to 
overestimate CVD risk in the Polish HAPIEE sample [37]. Also, 
classification into the groups of high and very high CVD risk 
could be biased as compared to real risk. Finally, the expert 
consensus for measurement of aortic stiffness recommends 
use of 80% of the direct carotid-femoral distance as the most 
accurate distance estimate [18]; however, we performed our 
measurements using the protocol of the device used in the 
study (Complior® system).
Our study is the first to describe the distribution of 
CFPWV in the adult urban Polish population. SCORE ≥ 5% 
predicted high CFPWV in 4.9 years of follow-up, which was 
independent of other risk factors, and CFPWV > 11.7 ap-
peared to be most valid in relation to high CVD risk.
Table 2. Age-adjusted relations between the high carotid-femoral pulse wave velocity (> 10 m/s) and blood pressure, obesity, 
blood lipids, smoking, and Systemic COronary Risk Estimation
Variable Age adjusted OR (95% CI)
Women Men
Diastolic BP, per 1 mmHg increase 1.04 (1.01–1.06) 1.02 (0.99–1.05)
Systolic BP, per 1 mmHg increase 1.03 (1.01–1.04) 1.02 (1.01–1.04)
MAP, per 1 mmHg increase 1.04 (1.01–1.06) 1.02 (1.001–1.05)
Hypertension*, yes vs. no 2.56 (1.52–4.29) 1.63 (0.95–2.83)
BMI, per 1 kg/m2 increase 1.11 (1.04–1.18) 1.07 (0.99–1.15)
Waist circumference, per 1 cm increase 1.03 (1.01–1.05) 1.02 (0.99–1.04)
Glucose, per 1 mmol/L increase 1.34 (0.95–1.88) 1.34 (1.01–1.79)
TC, per 1 mmol/L increase 1.13 (0.89–1.44) 1.33 (1.002–1.76)
TG, per 1 mmol/L increase 1.46 (0.98–2.72) 0.94 (0.68–1.29)
Smoking (current vs. non- and ex-smokers) 0.84 (0.47–1.49) 0.80 (0.46–1.41)
SCORE, per 1% increase 1.42 (1.11–1.81) 1.01 (0.95–1.07)
*Systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg and/or at BP lowering treatment; CI — confidence interval; MAP — mean arterial pressure; 
OR — odds ratio; other abbreviations — see Table 1
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